Drug interactions between Equetro and Geodon
Results for the following 2 drugs: |
|
|---|---|
| Equetro (carbamazepine) | |
| Geodon (ziprasidone) | |
Interactions between your selected drugs
carbamazepine ⇔ ziprasidone
Applies to: Equetro (carbamazepine) and Geodon (ziprasidone)
Coadministration with drugs that are inducers of the CYP450 3A4 isoenzyme may only modestly decrease the plasma concentrations of ziprasidone, as less than 1/3 of ziprasidone metabolic clearance occurs via oxidation mediated by CYP450 3A4. In nine healthy subjects, pretreatment with the potent CYP450 3A4 inducer carbamazepine (100 mg/day titrated to 400 mg/day over 5 days) for 25 days decreased the mean peak plasma concentration (Cmax) and 12-hour area under the concentration-time curve (AUC) of ziprasidone (20 mg orally twice a day for 3 days) by 27% and 36%, respectively, compared to when ziprasidone was administered alone. The half-life was decreased by 1 hour. These changes, although statistically significant, were not considered clinically important. There were also no serious adverse events or clinically significant alterations in ECG or vital signs throughout the study. These findings suggest that ziprasidone dose modifications are unlikely to be necessary in patients receiving potent CYP450 3A4 inducers.
See also...
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2009 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
